An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).

(2017) R. J. Buckanovich et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

(2015) S. Fu et al.   ANNALS OF ONCOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

(2015) S. Kummar et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

(2015) G. Kim et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

(2015) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research

(2015) Angiolo Gadducci et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Improvements in Progression-Free and Overall Survival Due to the Use of Anti-Angiogenic Agents in Gynecologic Cancers

(2015) Bernd C. Schmid et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

(2015) Robert L. Coleman et al.   GYNECOLOGIC ONCOLOGY

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

(2015) H. Hirte et al.   GYNECOLOGIC ONCOLOGY

WEE1 Kinase As a Target for Cancer Therapy

(2015) Sabine Mueller et al.   JOURNAL OF CLINICAL ONCOLOGY

Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development

(2015) Clare L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

(2015) Sandro Pignata et al.   LANCET ONCOLOGY

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

(2015) M. Aarts et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor

(2015) Y. Zhao et al.   ONCOLOGIST

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

(2015) Evelyn Despierre et al.   Targeted Oncology

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

(2015) Sarina A. Piha-Paul et al.   Oncotarget

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

(2015) Jennifer J. Wheler et al.   Oncotarget

The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma

(2015) Marta Cesca et al.   NEOPLASIA

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†

(2014) I. A. McNeish et al.   ANNALS OF ONCOLOGY

A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib

(2014) Subhajit Roy et al.   Anti-Cancer Agents in Medicinal Chemistry

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

(2014) G Del Conte et al.   BRITISH JOURNAL OF CANCER

The MAPK pathway across different malignancies: A new perspective

(2014) Mauricio Burotto et al.   CANCER

HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells

(2014) S. Lal et al.   CANCER RESEARCH

Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904

(2014) Robert L. Coleman et al.   EUROPEAN JOURNAL OF CANCER

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer

(2014) Angeles Alvarez Secord et al.   GYNECOLOGIC ONCOLOGY

Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer

(2014) Anita Schwandt et al.   INVESTIGATIONAL NEW DRUGS

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

(2014) Andreas du Bois et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses

(2014) Jung-Min Lee et al.   JNCI-Journal of the National Cancer Institute

Ovarian cancer

(2014) Gordon C Jayson et al.   LANCET

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

(2014) Joyce F Liu et al.   LANCET ONCOLOGY

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

(2014) Jonathan Ledermann et al.   LANCET ONCOLOGY

Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary

(2014) Tomoyuki Sasano et al.   MOLECULAR CANCER RESEARCH

Comprehensive Profiling of EGFR/HER Receptors for Personalized Treatment of Gynecologic Cancers

(2014) Henry D. Reyes et al.   Molecular Diagnosis & Therapy

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute

(2014) John D. Hainsworth et al.   Cancer Medicine

Targeting the PDGF signaling pathway in tumor treatment

(2013) Carl-Henrik Heldin   Cell Communication and Signaling

Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

(2013) T. Liu et al.   CLINICAL CANCER RESEARCH

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

(2013) J. E. Ang et al.   CLINICAL CANCER RESEARCH

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer

(2013) Joyce F. Liu et al.   EUROPEAN JOURNAL OF CANCER

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

(2013) Federica Tomao et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma

(2013) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

(2013) Philipp Harter et al.   INVESTIGATIONAL NEW DRUGS

A Wee1 checkpoint inhibits anaphase onset

(2013) Noel Lianga et al.   JOURNAL OF CELL BIOLOGY

Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer

(2013) Ignace B. Vergote et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study

(2013) Ignace B. Vergote et al.   JOURNAL OF CLINICAL ONCOLOGY

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

(2013) Shahneen K Sandhu et al.   LANCET ONCOLOGY

Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary

(2013) T. Hisamatsu et al.   MOLECULAR CANCER THERAPEUTICS

Latest research and treatment of advanced-stage epithelial ovarian cancer

(2013) Robert L. Coleman et al.   Nature Reviews Clinical Oncology

Protein kinase C and cancer: what we know and what we do not

(2013) R Garg et al.   ONCOGENE

SRChing for the substrates of Src

(2013) A B Reynolds et al.   ONCOGENE

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy

(2012) K. H. Baumann et al.   ANNALS OF ONCOLOGY

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

(2012) S Kaye et al.   BRITISH JOURNAL OF CANCER

A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer

(2012) A. A. Secord et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity

(2012) J. Moroney et al.   CLINICAL CANCER RESEARCH

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

(2012) S. Kummar et al.   CLINICAL CANCER RESEARCH

Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo

(2012) F. Simpkins et al.   CLINICAL CANCER RESEARCH

EGFR/HER-targeted therapeutics in ovarian cancer

(2012) Jason A Wilken et al.   Future Medicinal Chemistry

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

(2012) Siqing Fu et al.   GYNECOLOGIC ONCOLOGY

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2012) Russell J. Schilder et al.   GYNECOLOGIC ONCOLOGY

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma

(2012) Susana M. Campos et al.   GYNECOLOGIC ONCOLOGY

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma

(2012) Munmun Rahman et al.   HUMAN PATHOLOGY

Editorial

(2012) Uziel Beller   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

(2012) John Farley et al.   LANCET ONCOLOGY

Protein kinase C, an elusive therapeutic target?

(2012) Daria Mochly-Rosen et al.   NATURE REVIEWS DRUG DISCOVERY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

The clinical development of inhibitors of poly(ADP-ribose) polymerase

(2011) H. Calvert et al.   ANNALS OF ONCOLOGY

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

(2011) F A Raja et al.   BRITISH JOURNAL OF CANCER

Targeting Src in Mucinous Ovarian Carcinoma

(2011) Koji Matsuo et al.   CLINICAL CANCER RESEARCH

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study

(2011) Lubomir Bodnar et al.   GYNECOLOGIC ONCOLOGY

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

(2011) Lydia Usha et al.   GYNECOLOGIC ONCOLOGY

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group

(2011) R. Ramasubbaiah et al.   GYNECOLOGIC ONCOLOGY

Overview of anti-angiogenic agents in development for ovarian cancer

(2011) Robert A. Burger   GYNECOLOGIC ONCOLOGY

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma

(2011) S. John Weroha et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

(2011) Kian Behbakht et al.   GYNECOLOGIC ONCOLOGY

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

(2011) Agustin A. Garcia et al.   GYNECOLOGIC ONCOLOGY

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

(2011) Jonathan A. Ledermann et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer

(2011) Stan B. Kaye et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

(2010) J. J. Biagi et al.   ANNALS OF ONCOLOGY

In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma

(2010) Shahryar E. Mir et al.   CANCER CELL

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer

(2010) Martin Pölcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2

(2010) C. M. Annunziata et al.   CLINICAL CANCER RESEARCH

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)

(2010) H. Hirte et al.   GYNECOLOGIC ONCOLOGY

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment

(2010) Stephanie V. Blank et al.   GYNECOLOGIC ONCOLOGY

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

(2010) Michael Friedlander et al.   GYNECOLOGIC ONCOLOGY

Carboplatin and Paclitaxel in Combination With Oral Enzastaurin in Advanced Ovarian or Primary Peritoneal Cancer

(2010) Ignace Vergote et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer

(2010) Stephen A. Welch et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval

(2010) Peter C. Fong et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial

(2010) Daniela Matei et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

(2009) A. du Bois et al.   ANNALS OF ONCOLOGY

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors

(2009) D. Ross Camidge et al.   ANTI-CANCER DRUGS

mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary

(2009) S. Mabuchi et al.   CLINICAL CANCER RESEARCH

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

(2008) Chunhua Lu et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

(2008) Shem Patyna et al.   TOXICOLOGIC PATHOLOGY